Table 1.
Primary Efficacy Results as Determined by PANSS Total Score6
| Study Number | Treatment Group | Mean Baseline Score (SD) | LS Mean Change from Baseline (SE) | Placebo-Subtracted Differencea (95% CI) |
|---|---|---|---|---|
| Study 1 | Aripiprazole lauroxil 441 mgb | 92.6 (10.2) | −20.9 (1.4) | −10.9 (−14.5 to −7.3) |
| Aripiprazole lauroxil 882 mgb | 92.0 (10.8) | −21.8 (1.4) | −11.9 (−15.4 to −8.3) | |
| Placebo | 93.9 (11.3) | −9.8 (1.4) | – |
CI = confidence interval, not adjusted for multiple comparisons; LS Mean = least-squares mean; PANSS = Positive and Negative Syndrome Scale; SD = standard deviation; SE = standard error.
a
Difference (drug minus placebo) in least-squares mean change from baseline
b
Doses that are demonstrated to be effective